Lead Product(s) : Alisporivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Research Against Covid-19 Launched IN France with Debiopharm’s Antiviral Alisporivir
Details : Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of SARS-COV-2 (COVID-19).
Product Name : Debio 025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : Alisporivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
